Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind placebo-controlled study of HDM1002 tablets in treatment-naive adults with type 2 diabetes mellitus inadequately controlled with diet and exercise
CTR20252774Phase 3Active
- Sponsor
- 杭州中美华东制药有限公司 (Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.)
- Start
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of conveglipron in type 2 diabetes mellitus (T2DM), sponsored by 杭州中美华东制药有限公司 (Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.). Started Aug 2025; status: active.
02
Drugs
conveglipron
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on CTR20252774.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20252774.